Vaccine diplomacy: China in the Global South

Art by Gabriella Turrisi

As Western countries began rolling out COVID-19 vaccines last week, the UAE became the first nation to authorize use of one of China's vaccines against the coronavirus. Beijing promises a major breakthrough towards ending the pandemic for billions of people across the developing world, but it comes with risks for China, and strings attached for its customers.

First, the good news. According to the Emiratis, China's Sinopharm vaccine is 86 percent effective, slightly less than Pfizer's and Moderna's but more than expected just weeks ago. It's relatively cheap to make and only requires refrigeration, a game-changer for developing nations that lack large-scale cold-storage facilities.

Chinese vaccine makers are looking at a revenue windfall, and poor nations that may soon be able to quickly inoculate large numbers of people won't have to wait as long as they feared to begin to rebuild their economies.

Now the bad news. Chinese officials have largely contained the coronavirus at home and don't need to immediately vaccinate as big a percentage of its citizens as the US does to return to normalcy. But they will need to find the right division of supplies between 1.4 billion Chinese and the foreign countries that Chinese companies have agreed to supply. A fresh COVID-19 outbreak inside China without full domestic immunization could deal President Xi Jinping a heavy political blow.

Indeed, logistics is a big problem. Sinopharm claims it can produce up to 1 billion doses — enough to inoculate 500 million people with two doses each — in 2021. China has four other vaccine candidates in phase III clinical trials and could technically ramp up production to more than 3 billion doses next year, but it will prioritize certain countries in Southeast Asia, Africa, and Latin America.

Then there are concerns over safety. Chinese firms haven't been as forthcoming with data on their clinical trials as their Western rivals in the global vaccine race. That doesn't mean their products are unsafe, but some countries that have agreed to test them on their own citizens are wary about the lack of transparency. If the results are less than promised or vaccinations produce serious side-effects, everybody loses.

China has much to gain from its vaccine diplomacy efforts. A successful drug could do a lot to restore global faith in China, whose reputation has been severely damaged by its cover-up of the initial COVID-19 outbreak in Wuhan. Beijing says it's offering its medicine to poor countries as a "public good" with soft loans to purchase vaccines. Meanwhile, the West is engaging in "vaccine nationalism" by inoculating their own people first and selling (most of) the rest for profit.

On the other hand, China's vaccine diplomacy targets neither the US nor Western countries. Its goal is to supply the Global South, where Beijing can exercise its "soft power" by giving developing nations access to the drugs that only 20 percent of their people would receive by the end of next year under the international COVAX Facility to ensure equitable distribution of vaccines.

However, all this largesse may come with a catch. Countless recipients of Chinese loans have fallen deep into China's debt trap. If they default, a state-owned Chinese company may take over strategic infrastructure. With the vaccines, however, Beijing has learned its lesson after suffering a backlash over its ham-fisted "PPE diplomacy" at the onset of the pandemic.

With vaccines, China is unlikely to make the ties too explicit, but will expect countries to scratch their back too by being friendly to Chinese interests, or at least not overly hostile on sensitive political issues. This is now evident in Turkey — which is already turning a blind eye to China's treatment of its fellow Turkic Uighurs in China's Xinjiang region in order to get early access to Sinovac's drug — and Indonesia, another country undergoing Sinovac clinical trials that has toned down its criticisms of China's claim to the contested South China Sea.

At the end of the day, though, developing countries don't have much choice. Many can't wait until all rich countries inoculate their way to herd immunity, and will roll the dice on a Chinese vaccine that may not be as effective or safe, but will offer some quick public health and economic relief. The full price of this option will become clear over time.

Early employment can set a young person on a trajectory for success, providing both a paycheck and a stepping-stone for improving academic performance.

Bank of America is committed to investing in youth employment, funding $160 million since 2018 to connect youth and young adults to jobs and mentoring.

The minutiae of supply chains makes for boring dinner table talk, but it's increasingly becoming a hot topic of conversation now that packages are taking much longer to arrive in the consumer-oriented US, while prices of goods soar.

With the issue unlikely to be resolved anytime soon, right-wing media have dubbed President Biden the Grinch Who Stole Christmas, conjuring images of sad Christmas trees surrounded by distraught children whose holiday gifts are stuck somewhere in the Pacific Ocean.

It hasn't been a good run for Uncle Joe in recent months. What issues are tripping him up?

More Show less

Three years ago, Facebook changed its algorithms to mitigate online rage and misinformation. But it only made Facebook worse by boosting toxic engagement, says Nick Thompson, The Atlantic CEO & former WIRED editor-in-chief. Thompson believes Facebook simply got in over its head, rather than becoming intentionally "evil" like, say, Big Tobacco with cigarettes. "I think they just created something they couldn't control. And I think they didn't grasp what was happening until too late." Watch his interview with Ian Bremmer on the latest episode of GZERO World.

From overall health and wellness to representation in the global workforce, women and girls have faced serious setbacks over the past 18+ months. They also hold the key to more robust and inclusive growth in the months and years ahead: McKinsey & Company estimates that centering recovery efforts on women could contribute $13 trillion to global GDP by 2030.

On October 28th at 12pm ET, as part of our "Measuring What Matters" series, GZERO Media and the Bill & Melinda Gates Foundation will look beyond traditional indicators of economic recovery to examine COVID-19's impact on girls and women, specifically in the areas of health and employment.

More Show less

This year, American kids who've asked Santa for L.O.L. Surprise! dolls, Nerf blasters, or classic Legos may be disappointed. The delivery of these and other in-demand toys could be delayed due to pandemic-related supply chain disruptions that are still hitting US businesses and consumers hard. Container vessels loaded with precious cargo are waiting days to enter busy US ports, while within the country truck drivers are working flat out to meet soaring demand for goods of all kinds. Products are getting wildly expensive or arriving late. Here's a snapshot of the problem, showing longer delivery times, skyrocketing freight and shipping costs, and trucker employment.

Bolsonaro accused of crimes against humanity: A long-running Senate investigation in Brazil has found that by downplaying the severity of COVID, dithering on vaccines, and promoting quack cures, President Jair Bolsonaro directly caused the deaths of hundreds of thousands of people. An earlier version of the report went so far as to recommend charges of homicide and genocide as well, but that was pulled back in the final copy to a mere charge of "crimes against humanity", according to the New York Times. The 1,200-page report alleges Bolsonaro's policies led directly to the deaths of at least half of the 600,000 Brazilians who have succumbed to the virus. It's a bombshell charge, but it's unlikely to land Bolsonaro in the dock — for that to happen he'd have to be formally accused by the justice minister, an ally whom he appointed, and the lower house of parliament, which his supporters control. Still, as the deeply unpopular Bolsonaro limps towards next year's presidential election, a rap of this kind isn't going to help.

More Show less

11,412: Irmgard Furchner, a 92-year-old former typist at a Nazi concentration camp in Germany, is facing trial for contributing to the murder of 11,412 people there. Furchner tried to escape German authorities in late September by sneaking out of her nursing home, but was arrested hours later and slapped with an electronic wrist tag.

More Show less

If you had to guess which current world leader has made the most trips to Africa, who would you say? China's Xi Jinping? Nope, hardly — he's been there just four times. France's Emmanuel Macron? Pas de tout.

The answer may surprise you: it's Turkish President Recep Tayyip Erdogan, who's been to the continent more times than the leader(s) of any other non-African state. Just this week he notched his 28th visit, with stops in Angola, Nigeria, and Togo. Sure, being in power for two decades creates a lot of opportunities for exotic travel, but even Russia's Vladimir Putin isn't close: he's been to Africa just five times, all to visit South Africa or Egypt.

More Show less

Subscribe to GZERO Media's newsletter, Signal


Subscribe to GZERO Media's newsletter: Signal


Subscribe to GZERO Media's newsletter: Signal